SHAREHOLDERS' EQUITY (Tables)
|
6 Months Ended |
Jun. 30, 2025 |
|---|
| Stockholders' Equity Note [Abstract] |
|
| Schedule of ordinary shares reserved for future issuance |
| |
|
June 30,
2025
|
|
|
December 31,
2024
|
|
| |
|
(Unaudited)
|
|
|
|
|
| |
|
|
|
|
|
|
|
Ordinary shares
|
|
|
51,551,462
|
|
|
|
50,773,337
|
|
|
Outstanding share options and RSUs
|
|
|
3,032,942
|
|
|
|
3,164,395
|
|
|
Shares available for future grants under the 2021 plan
|
|
|
10,871,688
|
|
|
|
8,941,243
|
|
|
Shares available for future grants under the 2024 Foundation plan
|
|
|
14,410
|
|
|
|
15,000
|
|
|
Shares subject to the employee share purchase plan
|
|
|
1,118,576
|
|
|
|
1,156,437
|
|
|
Total
|
|
|
66,589,078
|
|
|
|
64,050,412
|
|
|
| Schedule of share option activity |
| |
|
Number of Options
|
|
|
Weighted-Average Exercise Price
|
|
|
Weighted Average Remaining Contractual life
|
|
|
Aggregate Intrinsic Value
|
|
| |
|
(Unaudited)
|
|
|
Outstanding — January 1, 2025 (*)
|
|
|
1,768,230
|
|
|
$
|
62.90
|
|
|
|
6.04
|
|
|
$
|
305,379
|
|
|
Granted (*)
|
|
|
42,897
|
|
|
$
|
0.87
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(415,101
|
)
|
|
$
|
38.74
|
|
|
|
|
|
|
|
|
|
|
Expired and forfeited
|
|
|
(34,323
|
)
|
|
$
|
54.03
|
|
|
|
|
|
|
|
|
|
|
Outstanding — June 30, 2025
|
|
|
1,361,703
|
|
|
$
|
68.54
|
|
|
|
5.68
|
|
|
$
|
334,903
|
|
|
Exercisable — June 30, 2025 (*)
|
|
|
1,134,484
|
|
|
$
|
64.20
|
|
|
|
5.34
|
|
|
$
|
283,937
|
|
(*) Includes 73,074 performance options granted to the Company’s Co-CEOs in 2022, 74,108 in 2023, 22,481 in 2024, and 20,217 in 2025, as applicable.
|
| Schedule of unvested restricted stock units |
| |
|
Number of Units
|
|
|
Weighted-Average Fair Value
|
|
| |
|
(Unaudited)
|
|
| |
|
|
|
|
|
|
|
Balance at January 1, 2025 (*)
|
|
|
1,396,165
|
|
|
$
|
177.72
|
|
|
Granted (*)
|
|
|
696,448
|
|
|
$
|
269.61
|
|
|
Vested
|
|
|
(325,163
|
)
|
|
$
|
175.71
|
|
|
Canceled
|
|
|
(96,211
|
)
|
|
$
|
176.79
|
|
|
Balance at June 30, 2025 (*)
|
|
|
1,671,239
|
|
|
$
|
216.46
|
|
(*) Includes 22,928 performance shares granted to the Company’s Co-CEOs in 2023, and 48,129 and 62,211 performance shares granted to the Company’s Co-CEOs and several executives in 2024 and 2025, respectively.
|
| Schedule of share-based compensation expense |
| |
|
Six months ended June 30,
|
|
| |
|
2025
|
|
|
2024
|
|
| |
|
|
|
|
|
|
|
Cost of revenues
|
|
$
|
3,406
|
|
|
$
|
3,116
|
|
|
Research and development
|
|
|
43,347
|
|
|
|
23,193
|
|
|
Sales and marketing
|
|
|
19,205
|
|
|
|
18,068
|
|
|
General and administrative
|
|
|
21,645
|
|
|
|
18,789
|
|
|
Share-based compensation, net of amounts capitalized
|
|
$
|
87,603
|
|
|
$
|
63,166
|
|
|
Capitalized share-based compensation expense
|
|
|
1,055
|
|
|
|
648
|
|
|
Total share-based compensation
|
|
$
|
88,658
|
|
|
$
|
63,814
|
|
|
| Schedule of black-scholes stock option assumptions used at the grant dates |
| |
|
Six months ended June 30,
|
|
| |
|
2025
|
|
|
2024
|
|
| |
|
(Unaudited)
|
|
|
Risk-free interest rate
|
|
|
3.74%-4.1%
|
|
|
|
4.03%-4.77%
|
|
|
Expected dividend yield
|
|
|
0%
|
|
|
|
0%
|
|
|
Expected term (in years)
|
|
|
2-7
|
|
|
|
5-7
|
|
|
Expected volatility
|
|
|
57.02%-59.32%
|
|
|
|
57.81%
|
|
|